Search

Displaying results 6551 - 6560 of 10000 in total
  1. Drug

    Interferon Kappa

    go.drugbank.com/drugs/DB15749
    Experimental

    a 27-amino acid signal peptide conserved in type I interferons. … Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and

  2. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    Pradefovir mesilate (previously known as MB-06886, Hepavir B and remofovir mesylate) is an orally administered small molecule compound that belongs to a novel series of phosphate and phosphonate prodrugs … [Adefovir] (Hepsera) is an acyclic phosphonate analogue of adenine that is used to treat hepatitis B virus.

  3. Drug

    Phosphorus P-32

    go.drugbank.com/drugs/DB14551
    Investigational

    Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. … Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular

  4. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. … Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.

  5. Drug

    PGX-100

    go.drugbank.com/drugs/DB06114
    Investigational

    PGX-100 is an intravenous dosage form of modified heparin. … It is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity.

  6. Drug

    Meglutol

    go.drugbank.com/drugs/DB04377
    Experimental

    An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids. … It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which

  7. Drug

    Fezolinetant

    go.drugbank.com/drugs/DB15669
    ApprovedInvestigational

    [A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms can significantly affect quality of life, as women with 7 or more moderate to severe VMS daily have reported a decline in sleep … [A259606] Estrogen is a potent neuromodulator, particularly in the hypothalamus, and has been shown to be involved as a negative regulator in generating Gonadotropin-releasing hormone (GnRH) pulse through

  8. Drug

    Zastaprazan

    go.drugbank.com/drugs/DB21524
    Investigational

    Zastaprazan has a monoisotopic molecular weight of 362.21 Da. … Zastaprazan is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Zastaprazan is a proton pump inhibitor, not dependent on acid activation.

  9. Drug

    Linaprazan

    go.drugbank.com/drugs/DB20602
    Investigational

    Linaprazan has a monoisotopic molecular weight of 366.21 Da. … Linaprazan is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Linaprazan is a proton pump inhibitor, not dependent on acid activation.

  10. Drug

    Prusogliptin

    go.drugbank.com/drugs/DB20606
    Investigational

    Prusogliptin has a monoisotopic molecular weight of 324.2 Da. … Prusogliptin is a small molecule drug. The usage of the INN stem '-gliptin' in the name indicates that Prusogliptin is a dipeptidyl aminopeptidase-IV inhibitor.